FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4286296457> ?p ?o ?g. }

• W4286296457 endingPage "12107" @default.
• W4286296457 startingPage "12107" @default.
• W4286296457 abstract "12107 Background: Chemotherapy-induced nausea and vomiting (CINV), a major adverse effect of cancer treatment, can attenuate life quality. Multiple international antiemetic guidelines have recommended a 4-drug regimen (corticosteroid, 5-HT3 receptor antagonist, NK-1 receptor antagonist, and the antipsychotic medication olanzapine) for decreasing highly emetogenic CINV. This raised a question regarding whether antiemetic therapy regimens for highly emetogenic chemotherapy could be de-intensified, decreasing cost and side effects from anti-emetogenic agents. Methods: Study A221602 was developed to compare two olanzapine-containing antiemetic regimens, one with the use of an NK-1 receptor antagonist (aprepitant or fosaprepitant) and one without. Patients (pts) received intravenous highly emetogenic chemotherapy as either 1) cisplatin, given on one day, at a dose of ≥ 70 mg/m2, with or without other chemotherapy agent(s) or 2) doxorubicin (60 mg/m2) plus cyclophosphamide (600 mg/m2) on one day. Pts in both arms received 1) a 5-HT 3 receptor antagonist (palonosetron 0.25 mg IV or ondansetron 8-16 mg IV or 16-24 mg PO,) on day one, 2) dexamethasone (12 mg PO, day one followed by 8 mg PO, days 2-4), and 3) olanzapine (10 mg/day PO, days 1 to 4). On Day 1, all agents were given prior to chemotherapy, with the exception that olanzapine could be taken prior to chemotherapy or at bedtime. Additionally, pts were randomized to receive an NK-1 receptor antagonist (fosaprepitant 150 mg IV or aprepitant 130 mg IV; 346 pts) or a matching placebo (344 pts). The primary objective was to compare the proportion of patients with no nausea for 5 days following receipt of their chemotherapy between the two study arms. Results: While there was no suggestion of outcome differences on day 1 between the two study arms, fewer pts (7.4%; upper limit of the 95% confidence interval was 13.5%) without NK-1 receptor antagonists were without nausea for the complete 5-day study period. Conclusions: Per the study design, created to exclude a 10% benefit for NK-1 receptor antagonists, the results did not provide sufficient evidence to reject the hypothesis that the 4-drug regimen was superior to the protocol 3-drug regimen (p=0.24). Support: UG1CA189823; Clinical trial information: NCT03578081." @default.
• W4286296457 created "2022-07-21" @default.
• W4286296457 creator A5008767553 @default.
• W4286296457 creator A5027044033 @default.
• W4286296457 creator A5027347053 @default.
• W4286296457 creator A5029981224 @default.
• W4286296457 creator A5051244727 @default.
• W4286296457 creator A5057199961 @default.
• W4286296457 creator A5059982063 @default.
• W4286296457 creator A5067914284 @default.
• W4286296457 creator A5072347487 @default.
• W4286296457 creator A5076594436 @default.
• W4286296457 creator A5077959964 @default.
• W4286296457 creator A5082799664 @default.
• W4286296457 creator A5090729537 @default.
• W4286296457 creator A5091829641 @default.
• W4286296457 date "2022-06-01" @default.
• W4286296457 modified "2023-09-27" @default.
• W4286296457 title "Olanzapine with or without an NK-1 receptor antagonist for preventing chemotherapy-induced nausea and vomiting in patients receiving highly emetogenic chemotherapy: A phase III randomized, double-blind, placebo-controlled trial (ALLIANCE A221602)." @default.
• W4286296457 doi "https://doi.org/10.1200/jco.2022.40.16_suppl.12107" @default.
• W4286296457 hasPublicationYear "2022" @default.
• W4286296457 type Work @default.
• W4286296457 citedByCount "1" @default.
• W4286296457 countsByYear W42862964572022 @default.
• W4286296457 crossrefType "journal-article" @default.
• W4286296457 hasAuthorship W4286296457A5008767553 @default.
• W4286296457 hasAuthorship W4286296457A5027044033 @default.
• W4286296457 hasAuthorship W4286296457A5027347053 @default.
• W4286296457 hasAuthorship W4286296457A5029981224 @default.
• W4286296457 hasAuthorship W4286296457A5051244727 @default.
• W4286296457 hasAuthorship W4286296457A5057199961 @default.
• W4286296457 hasAuthorship W4286296457A5059982063 @default.
• W4286296457 hasAuthorship W4286296457A5067914284 @default.
• W4286296457 hasAuthorship W4286296457A5072347487 @default.
• W4286296457 hasAuthorship W4286296457A5076594436 @default.
• W4286296457 hasAuthorship W4286296457A5077959964 @default.
• W4286296457 hasAuthorship W4286296457A5082799664 @default.
• W4286296457 hasAuthorship W4286296457A5090729537 @default.
• W4286296457 hasAuthorship W4286296457A5091829641 @default.
• W4286296457 hasConcept C118552586 @default.
• W4286296457 hasConcept C126322002 @default.
• W4286296457 hasConcept C142724271 @default.
• W4286296457 hasConcept C204787440 @default.
• W4286296457 hasConcept C27081682 @default.
• W4286296457 hasConcept C2776412080 @default.
• W4286296457 hasConcept C2776619155 @default.
• W4286296457 hasConcept C2776712918 @default.
• W4286296457 hasConcept C2779924295 @default.
• W4286296457 hasConcept C2780574406 @default.
• W4286296457 hasConcept C2780580376 @default.
• W4286296457 hasConcept C2780852908 @default.
• W4286296457 hasConcept C2780884295 @default.
• W4286296457 hasConcept C42219234 @default.
• W4286296457 hasConcept C71924100 @default.
• W4286296457 hasConcept C90924648 @default.
• W4286296457 hasConcept C98274493 @default.
• W4286296457 hasConceptScore W4286296457C118552586 @default.
• W4286296457 hasConceptScore W4286296457C126322002 @default.
• W4286296457 hasConceptScore W4286296457C142724271 @default.
• W4286296457 hasConceptScore W4286296457C204787440 @default.
• W4286296457 hasConceptScore W4286296457C27081682 @default.
• W4286296457 hasConceptScore W4286296457C2776412080 @default.
• W4286296457 hasConceptScore W4286296457C2776619155 @default.
• W4286296457 hasConceptScore W4286296457C2776712918 @default.
• W4286296457 hasConceptScore W4286296457C2779924295 @default.
• W4286296457 hasConceptScore W4286296457C2780574406 @default.
• W4286296457 hasConceptScore W4286296457C2780580376 @default.
• W4286296457 hasConceptScore W4286296457C2780852908 @default.
• W4286296457 hasConceptScore W4286296457C2780884295 @default.
• W4286296457 hasConceptScore W4286296457C42219234 @default.
• W4286296457 hasConceptScore W4286296457C71924100 @default.
• W4286296457 hasConceptScore W4286296457C90924648 @default.
• W4286296457 hasConceptScore W4286296457C98274493 @default.
• W4286296457 hasFunder F4320332161 @default.
• W4286296457 hasIssue "16_suppl" @default.
• W4286296457 hasLocation W42862964571 @default.
• W4286296457 hasOpenAccess W4286296457 @default.
• W4286296457 hasPrimaryLocation W42862964571 @default.
• W4286296457 hasRelatedWork W100286279 @default.
• W4286296457 hasRelatedWork W1480067006 @default.
• W4286296457 hasRelatedWork W2032642104 @default.
• W4286296457 hasRelatedWork W2057039455 @default.
• W4286296457 hasRelatedWork W2074600725 @default.
• W4286296457 hasRelatedWork W2134944372 @default.
• W4286296457 hasRelatedWork W2155434997 @default.
• W4286296457 hasRelatedWork W2233598186 @default.
• W4286296457 hasRelatedWork W2416018394 @default.
• W4286296457 hasRelatedWork W3096722963 @default.
• W4286296457 hasVolume "40" @default.
• W4286296457 isParatext "false" @default.
• W4286296457 isRetracted "false" @default.
• W4286296457 workType "article" @default.